Reuters logo
BRIEF-Arqule reports dosing in registrational trial of FGFR inhibitor
November 21, 2017 / 12:11 PM / 21 days ago

BRIEF-Arqule reports dosing in registrational trial of FGFR inhibitor

Nov 21 (Reuters) - Arqule Inc:

* Arqule announces dosing in a registrational trial of fgfr inhibitor, derazantinib, for treatment of intrahepatic cholangiocarcinoma

* Arqule Inc - ‍trial is being conducted with a biomarker assay to identify fgfr2 fusions​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below